Innovent Biologics Initiates Phase 3 Trial for Novel Multiple Myeloma Antibody

Innovent Biologics has begun its pivotal Phase 3 clinical trial in China for IBI3003, a tri-specific antibody targeting relapsed or refractory multiple myeloma. This study aims to evaluate the drug's effectiveness as a second to fifth-line treatment. The development addresses a significant unmet medical need for patients with this challenging blood cancer.